Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion

Molecular Oncology

Volumn 9, Issue 4, 2015, Pages 772-782

  Andrade, Victor P ^a,b   Morrogh, Mary ^a   Qin, Li Xuan ^a   Olvera, Narciso ^a   Giri, Dilip ^a   Muhsen, Shirin ^a   Sakr, Rita A ^a   Schizas, Michail ^a   Ng, Charlotte K Y ^a   Arroyo, Crispinita D ^a   Brogi, Edi ^a   Viale, Agnes ^a   Morrow, Monica ^a   Reis Filho, Jorge S ^a   King, Tari A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Breast cancer; Gene expression; Lobular carcinoma in situ; Precursor; Risk factor

Indexed keywords

PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; LASER CAPTURE MICRODISSECTION; LOBULAR CARCINOMA IN SITU; MASTECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR INVASION; WNT SIGNALING PATHWAY; BREAST TUMOR; CLUSTER ANALYSIS; COPY NUMBER VARIATION; DISEASE COURSE; DOWN REGULATION; EPITHELIUM; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC HETEROGENEITY; GENETICS; HUMAN CHROMOSOME; LUNG CARCINOMA; PATHOLOGY; SOFTWARE; TUMOR GENE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; CHROMOSOMES, HUMAN; CLUSTER ANALYSIS; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; DOWN-REGULATION; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; GENETIC HETEROGENEITY; HUMANS; NEOPLASM INVASIVENESS; SOFTWARE;

EID: 84926417597     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.12.005     Document Type: Article

References (33)

1. Andrade V.P., Ostrovnaya I., Seshan V.E., Morrogh M., Giri D., Olvera N., De Brot M., Morrow M., Begg C., King T. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res. 2012, 14:R103.
2. Aulmann S., Penzel R., Longerich T., Funke B., Schirmacher P., Sinn H.P. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res. Treat. 2008, 107:331-335.
3. Buerger H., Otterbach F., Simon R., Schafer K.L., Poremba C., Diallo R., Brinkschmidt C., Dockhorn-Dworniczak B., Boecker W. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J.Pathol. 1999, 189:521-526.
4. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast cancer. Nature 2012, 490:61-70.
5. Castaneda C.A., Cortes-Funes H., Gomez H.L., Ciruelos E.M. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 2010, 29:751-759.
6. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., Nielsen T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J.Natl. Cancer Inst. 2009, 101:736-750.
7. Cizkova M., Vacher S., Meseure D., Trassard M., Susini A., Mlcuchova D., Callens C., Rouleau E., Spyratos F., Lidereau R., Bieche I. PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer 2013, 13:545.
8. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1:707-717.
9. Da Silva L., Parry S., Reid L., Keith P., Waddell N., Kossai M., Clarke C., Lakhani S.R., Simpson P.T. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am. J. Surg. Pathol. 2008, 32:773-783.
10. Davis A.J., Yan Z., Martinez B., Mumby M.C. Protein phosphatase 2A is targeted to cell division control protein 6 by a calcium-binding regulatory subunit. J.Biol. Chem. 2008, 283:16104-16114.
11. Dorsam R.T., Gutkind J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 2007, 7:79-94.
12. Feeley L.P., Mulligan A.M., Pinnaduwage D., Bull S.B., Andrulis I.L. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod. Pathol. - An Official Journal of the United States and Canadian Academy of Pathology, Inc 2014, 27:554-561.
13. Hungermann D., Schmidt H., Natrajan R., Tidow N., Poos K., Reis-Filho J.S., Brandt B., Buerger H., Korsching E. Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J.Pathol. 2011, 224:517-528.
14. Hwang E.S., Nyante S.J., Yi Chen Y., Moore D., DeVries S., Korkola J.E., Esserman L.J., Waldman F.M. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004, 100:2562-2572.
15. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
16. Kojima S., Enokida H., Yoshino H., Itesako T., Chiyomaru T., Kinoshita T., Fuse M., Nishikawa R., Goto Y., Naya Y., Nakagawa M., Seki N. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J.Hum. Genet. 2014, 59:78-87.
17. Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., Van de Vijver M.J. WHO classification of tumors of the breast 2012, IARC, Lyon.
18. Lu Y.J., Osin P., Lakhani S.R., Di Palma S., Gusterson B.A., Shipley J.M. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998, 58:4721-4727.
19. Mastracci T.L., Boulos F.I., Andrulis I.L., Lam W.L. Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer. Breast Cancer Res. 2007, 9:215.
20. Mastracci T.L., Shadeo A., Colby S.M., Tuck A.B., O'Malley F.P., Bull S.B., Lam W.L., Andrulis I.L. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast. Genes Chromosomes Cancer 2006, 45:1007-1017.
21. Mastracci T.L., Tjan S., Bane A.L., O'Malley F.P., Andrulis I.L. E-cadherin alterations in a typical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod. Pathol. - An Official Journal of the United States and Canadian Academy of Pathology, Inc 2005, 18:741-751.
22. Monti S., Tamayo P., Mesirov J., Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 2003, 52:91-118.
23. Morrogh M., Andrade V.P., Giri D., Sakr R.A., Paik W., Qin L.X., Arroyo C.D., Brogi E., Morrow M., King T.A. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res. Treat. 2012, 132:641-652.
24. Morrogh M., Olvera N., Bogomolniy F., Borgen P.I., King T.A. Tissue preparation for laser capture microdissection and RNA extraction from fresh frozen breast tissue. Biotechniques 2007, 43. 41-42, 44, 46 passim.
25. Nishizaki T., Chew K., Chu L., Isola J., Kallioniemi A., Weidner N., Waldman F.M. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int. J. Cancer 1997, 74:513-517.
26. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J.Clin. Oncol. - Off. J. Am. Soc. Clin. Oncol. 2009, 27:1160-1167.
27. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
28. Rosen P.P., Kosloff C., Lieberman P.H., Adair F., Braun D.W. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am. J. Surg. Pathol. 1978, 2:225-251.
29. Sanchez-Carbayo M., Saint F., Lozano J.J., Viale A., Cordon-Cardo C. Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis. Clin. Chem. 2003, 49:2096-2100.
30. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. (Article3).
31. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10869-10874.
32. Stange D.E., Radlwimmer B., Schubert F., Traub F., Pich A., Toedt G., Mendrzyk F., Lehmann U., Eils R., Kreipe H., Lichter P. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin. Cancer Res. 2006, 12:345-352.
33. Vos C.B., Cleton-Jansen A.M., Berx G., de Leeuw W.J., ter Haar N.T., van Roy F., Cornelisse C.J., Peterse J.L., van de Vijver M.J. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br. J. Cancer 1997, 76:1131-1133.